Decoy Therapeutics Inc. (DCOY) stock
DCOYNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.98−0.08 (-7.56%)
Close on Nov 13, 2026Market cap $638.94KP/E –Yield –
Decoy Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Decoy Therapeutics's total assets was $8.79M at Sep 30, 2026. For fiscal 2025 it was $11.06M, up 265.8% from the year before. Over ten years it grew -19.4% a year on average. The highest annual figure on record is $95.07M in fiscal 2015.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.06M | +265.8% |
| FY2024 | Dec 31, 2024 | $3.02M | -54.1% |
| FY2023 | Dec 31, 2023 | $6.59M | -55.0% |
| FY2022 | Dec 31, 2022 | $14.65M | -64.1% |
| FY2021 | Dec 31, 2021 | $40.83M | +63.8% |
| FY2020 | Dec 31, 2020 | $24.93M | +79.4% |
| FY2019 | Dec 31, 2019 | $13.89M | +110.1% |
| FY2018 | Dec 31, 2018 | $6.61M | -81.1% |
| FY2017 | Dec 31, 2017 | $34.99M | -44.6% |
| FY2016 | Dec 31, 2016 | $63.21M | -33.5% |
| FY2015 | Dec 31, 2015 | $95.07M | +167.0% |
| FY2014 | Dec 31, 2014 | $35.61M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $8.79M | +44.2% |
| Q2 FY2026 | Jun 30, 2026 | $9.00M | +546.3% |
| Q1 FY2026 | Mar 31, 2026 | $8.42M | +260.1% |
| Q4 FY2025 | Dec 31, 2025 | $11.06M | +265.8% |
| Q3 FY2025 | Sep 30, 2025 | $6.10M | +58.0% |
| Q2 FY2025 | Jun 30, 2025 | $1.39M | -60.8% |
| Q1 FY2025 | Mar 31, 2025 | $2.34M | -52.1% |
| Q4 FY2024 | Dec 31, 2024 | $3.02M | -54.1% |
| Q3 FY2024 | Sep 30, 2024 | $3.86M | -54.1% |
| Q2 FY2024 | Jun 30, 2024 | $3.55M | -70.5% |
| Q1 FY2024 | Mar 31, 2024 | $4.88M | -51.4% |
| Q4 FY2023 | Dec 31, 2023 | $6.59M | -55.0% |
| Q3 FY2023 | Sep 30, 2023 | $8.40M | -57.4% |
| Q2 FY2023 | Jun 30, 2023 | $12.06M | -64.2% |
| Q1 FY2023 | Mar 31, 2023 | $10.06M | -71.7% |
| Q4 FY2022 | Dec 31, 2022 | $14.65M | -64.1% |
| Q3 FY2022 | Sep 30, 2022 | $19.72M | -55.4% |
| Q2 FY2022 | Jun 30, 2022 | $33.65M | -29.0% |
| Q1 FY2022 | Mar 31, 2022 | $35.51M | -30.1% |
| Q4 FY2021 | Dec 31, 2021 | $40.83M | +63.8% |
| Q3 FY2021 | Sep 30, 2021 | $44.26M | +91.9% |
| Q2 FY2021 | Jun 30, 2021 | $47.40M | +155.4% |
| Q1 FY2021 | Mar 31, 2021 | $50.77M | +153.0% |
| Q4 FY2020 | Dec 31, 2020 | $24.93M | +79.4% |
| Q3 FY2020 | Sep 30, 2020 | $23.06M | +59.5% |
| Q2 FY2020 | Jun 30, 2020 | $18.56M | +160.1% |
| Q1 FY2020 | Mar 31, 2020 | $20.07M | +145.2% |
| Q4 FY2019 | Dec 31, 2019 | $13.89M | +110.1% |
| Q3 FY2019 | Sep 30, 2019 | $14.46M | +3.7% |
| Q2 FY2019 | Jun 30, 2019 | $7.14M | -58.5% |
| Q1 FY2019 | Mar 31, 2019 | $8.18M | -68.6% |
| Q4 FY2018 | Dec 31, 2018 | $6.61M | -81.1% |
| Q3 FY2018 | Sep 30, 2018 | $13.94M | -66.2% |
| Q2 FY2018 | Jun 30, 2018 | $17.21M | -65.3% |
| Q1 FY2018 | Mar 31, 2018 | $26.03M | -53.1% |
| Q4 FY2017 | Dec 31, 2017 | $34.99M | -44.6% |
| Q3 FY2017 | Sep 30, 2017 | $41.21M | – |
| Q2 FY2017 | Jun 30, 2017 | $49.63M | – |
| Q1 FY2017 | Mar 31, 2017 | $55.50M | – |
| Q4 FY2016 | Dec 31, 2016 | $63.21M | – |
See a number that looks wrong?